Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN001 in Duchenne Muscular Dystrophy
NCT06328725Phase 2Not yet recruiting
- Sponsor
- ENCell
- Start
- Mar 2024
- Primary completion
- Nov 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EN001 in Duchenne muscular dystrophy (DMD), sponsored by ENCell. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
EN001
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06328725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328725.